Researchers develop web-based app to predict glioma mutations

A screenshot of the IDH1 prediction model designed by University of Kentucky researchers. Credit: University of Kentucky

A new web-based program developed by University of Kentucky Markey Cancer Center researchers will provide a simple, free way for healthcare providers to determine which brain tumor cases require testing for a genetic mutation.

Gliomas – a type of tumor that begins in the brain or spine – are the most common and deadly form of in adults, making up about 80 percent of cases. In some of these cases, patients have a mutation in a specific gene, known as an IDH1 mutation – and patients who have this tend to survive years longer than those who do not carry the mutation.

The program, developed by UK researchers Li Chen, Eric Durbin, and Craig Horbinski, uses a statistical model to accurately predict the likelihood that a patient carries the IDH1 mutation and requires screening. Healthcare providers need only answer four questions in the application.

Gliomas are often tested for IDH1 mutation following surgery to remove the tumor, but undergoing this type of testing often requires stringent insurance pre-approvals due to rising healthcare costs, Horbinski says.

"Currently, there are no universally accepted guidelines for when gliomas should be tested for this mutation," Horbinski said. "Obtaining insurance pre-approval for additional molecular testing is becoming more commonplace, and this program will assist with an evidence-based rationale for when IDH1 screening is necessary."

Additionally, Horbinski notes that the program will help conserve research dollars by helping brain cancer researchers narrow down which specific older gliomas in tumor banks – previously removed in a time before IDH1 testing was routine – should be tested as data for research projects.

add to favorites email to friend print save as pdf

Related Stories

Researchers erase human brain tumor cells in mice

Sep 23, 2013

Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of—and ultimately left no detectable trace of—brain tumor cells taken from adult ...

Recommended for you

Video: Is that double mastectomy really necessary?

15 hours ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments